Related Experiment Video

Updated: Jul 24, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

16.8K

Meeting report: Expert consultation on late arresting replication competent (LARC) malaria sporozoite vaccine

Annie X Mo1, Glen McGugan1, John T Pesce1

  • 1National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services , Rockville, MD 20852, USA.

Vaccine
|April 17, 2025
PubMed

Insights

Experts met in June 2024 to prioritize research for new whole Plasmodium falciparum sporozoite vaccines. The focus was on genetically attenuated, liver-stage arresting replication competent (LARC) sporozoite vaccines to combat malaria.

Area of Science:

  • Vaccinology
  • Infectious Diseases
  • Parasitology

Background:

  • Malaria remains a significant global health challenge, necessitating novel vaccine strategies.
  • Previous malaria vaccine research and implementation efforts offer valuable lessons for current development.
  • The World Health Organization (WHO) has established Preferred Product Characteristics (PPCs) for next-generation malaria vaccines.

Purpose of the Study:

  • To define strategic priorities for research and development of whole Plasmodium falciparum sporozoite vaccine candidates.
  • To focus on genetically attenuated, late (liver stage) arresting replication competent (LARC) sporozoite vaccines.
  • To align development with WHO PPCs and Target Product Profiles (TPPs) for LARC vaccines.

Main Methods:

  • Convened an expert consultation in June 2024.
  • Reviewed existing malaria vaccine R&D and implementation data.
  • Discussed critical features for LARC vaccine Target Product Profiles (TPPs) and development strategies.

Main Results:

  • Identified key knowledge gaps in LARC sporozoite vaccine development.
  • Outlined strategic priorities for future research and product development.
  • Highlighted opportunities for advancing LARC malaria vaccine candidates.

Conclusions:

  • Strategic alignment and focused research are crucial for developing effective LARC malaria sporozoite vaccines.
  • Addressing identified knowledge gaps will accelerate progress in malaria vaccine R&D.
  • Future efforts should prioritize LARC vaccine candidates based on expert consultation findings.
Keywords:
Clinical development plan (CDP)Development plan and strategyMalaria vaccinePlasmodium falciparum (Pf)Sporozoite (SPZ)Target product profile (TPP)

More Related Videos

Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites08:46

Myeloid Cell Isolation from Mouse Skin and Draining Lymph Node Following Intradermal Immunization with Live Attenuated Plasmodium Sporozoites

Published on: May 18, 2016

17.2K
Generating Genetically Modified Plasmodium berghei Sporozoites10:16

Generating Genetically Modified Plasmodium berghei Sporozoites

Published on: May 5, 2023

1.1K

Related Concept Videos

Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...